FDA Approves ResolutionMD for Diagnosis on Mobile Devices
Calgary Scientific’s ResolutionMD received FDA clearance for diagnosis on mobile devices for most imaging modalities.
ResolutionMD, an enterprise image-viewing solution, has been approved by the U.S. Food and Drug Administration (FDA) for diagnosis on mobile devices for most imaging modalities.
Calgary Scientific, Inc., the company behind ResolutionMD, worked with multiple radiologists worldwide to clinically validate the solution before submitting it to the FDA. ResolutionMD allows doctors to securely view patient images and reports from a variety of computers and mobile devices. It also offers the ability to collaborate with other practitioners and diagnose from any location.
The mobile medical diagnosis software of ResolutionMD can be integrated into any EMR and plugged into existing distributed storage systems. The FDA’s safety and effectiveness review found ResolutionMD to be substantially equivalent to PACS or dedicated diagnostic workstations.
ResolutionMD has been cleared to diagnose modalities such as CR, DR, radio-fluoroscopy, angiography, ultrasound, nuclear medicine, endoscopy and ophthalmology.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
